A5076699864- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- CAR-T cell therapy research
- Helicobacter pylori-related gastroenterology studies
- Frailty in Older Adults
- Obesity, Physical Activity, Diet
- Consumer Attitudes and Food Labeling
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Pancreatic and Hepatic Oncology Research
Merck & Co., Inc., Rahway, NJ, USA (United States)
2022-2024
Abstract Background: In the dose escalation phase of a first-in-human 1 study (NCT03564691), anti-ILT4 IgG4 monoclonal antibody MK-4830 + pembrolizumab (pembro) had manageable safety profile and demonstrated promising antitumor activity in patients (pts) with previously treated advanced solid tumors, including those PD on immunotherapy. Here, we present safety, efficacy, biomarker analyses for pembro pancreatic adenocarcinoma, glioblastoma, head neck squamous cell carcinoma (HNSCC), gastric...
4139 Background: Standard first-line treatment of mPDAC includes Gem/Nab-P doublet therapy, which typically results in an ORR 23%-35%, a median PFS 5-6 mo, and OS 7-10 mo. ILT3 is inhibitory receptor expressed on monocytic myeloid cells, including tolerogenic dendritic cells myeloid-derived suppressor cells. MK-0482 novel humanized IgG4 monoclonal antibody targeting ILT3. inhibition with has the potential to relieve immunosuppression within tumor microenvironment. In expansion cohort...
2046 Background: For patients with GBM, treatment options are limited once the disease has recurred and become inoperable after standard first-line therapy. ILT3 is an inhibitory receptor expressed on monocytic myeloid cells, including tolerogenic dendritic cells myeloid-derived suppressor (MDSCs). High expression of these immune been associated tolerance suppression T-cell function. Data have shown that GBMs high levels MDSCs within tumor microenvironment (TME). MK-0482 a novel humanized...
"CGE22-096: Trends in The Use of Comprehensive Genomic Profiling Among Older Patients With Advanced Cancer From 2018 to 2020 the United States: Findings SEQUENCE Study" published on 31 Mar 2022 by National Network.
e18755 Background: Until the global approval of pembrolizumab for treatment first line (1L) MSI-H/dMMR metastatic CRC (mCRC), newly diagnosed patients were managed with standard care (SOC) treatments like chemotherapy or without an EGFR/VEGF inhibitor, independent biomarker testing status. This study assessed RW SOC patterns and outcomes among 1L mCRC patients. Methods: A retrospective observational was conducted ≥18 years stage IV (index event) who received in US community-based Oncology...
9126 Background: As the number of approved molecularly-targeted therapies for treatment lung cancer increases, debate continues as to whether a clinical strategy leveraging next-generation sequencing (NGS) comprehensive genomic profiling (CGP) match patients targeted treatments is advantageous versus narrow/single-gene (N/S) panel testing. We examined and economic outcomes with advanced (aLC) in United States (US). Methods: In this retrospective study, newly diagnosed aLC aged 65-89 years...
Abstract Introduction/Purpose: Recent advances have led to approval of multiple new targeted drugs across a variety indications based on genomic markers. In part due the increasing number therapeutically actionable markers in many cancers, whether strategy upfront broad next-generation sequencing (NGS) could potentially improve selection patients for compared narrow/single gene panels remains uncertain. We examined recent trends proportions receiving sequencing-directed therapy following use...